[CAS NO. 485-72-3] Formononetin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [485-72-3]

Catalog

HY-N0183

Brand

MCE

CAS

485-72-3

DESCRIPTION [485-72-3]

Overview

MDL	MFCD00016948
Molecular Weight	268.26
Molecular Formula	C16H12O4
SMILES	O=C1C(C2=CC=C(OC)C=C2)=COC3=CC(O)=CC=C13

For research use only. We do not sell to patients.

7 Publications Citing Use of MCE

Summary

Formononetin is a potent FGFR2 inhibitor with an IC ₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth ^[1] .

IC50 & Target

FGFR2

4.31 μM (IC ₅₀ )

In Vitro

Formononetin is one of the major isoflavonoid constituents isolated from Astragalus membranaceus and has been demonstrated diverse pharmacological benefits. Formononetin possesses anti-angiogenic activity in human colon cancer cells. Formononetin also promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells ^[1] .
Formononetin (25 to 150 μM) markedly decreases the proliferation of endothelial cells stimulated by FGF2 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	HUVECs
Concentration:	0, 10, 25, 50, 75, 100, and 150 μM
Incubation Time:
Result:	Significantly decreased the proliferation of HUVECs stimulated by FGF2 in a dose-dependent manner, while had little inhibitory effects on HUVECs that were not stimulated by FGF2.

In Vivo

Formononetin dramatically suppresses tumor volumes and the Formononetin-treated group tumor weight are significantly inhibited compared with the vehicle group . Formononetin treatment is well tolerated, and there is no significant difference in weight between vehicle group and formononetin treated groups ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c nude mice bearing MDA-MB-231 xenografts ^[1]
Dosage:	100 mg/kg
Administration:	Treated daily by intragastric administration for 25 days
Result:	Inhibited breast cancer growth and angiogenesis in vivo.

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 35 mg/mL ( 130.47 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7277 mL	18.6386 mL	37.2773 mL
5 mM	0.7455 mL	3.7277 mL	7.4555 mL
10 mM	0.3728 mL	1.8639 mL	3.7277 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2.5 mg/mL (9.32 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (9.32 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Xiao Yu Wu,et al. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 2015 Dec 29;6(42):44563-78.

Synonyms

4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-

Formononetin

Isoflavone, 7-hydroxy-4′-methoxy-

7-Hydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one

7-Hydroxy-4′-methoxyisoflavone

Biochanin B

Formononetol

Daidzein 4′-methyl ether

NSC 93360

Flavosil

Formonetin

7-Hydroxy-3-(4-methoxyphenyl)chromen-4-one

Myconate

Formonentin

6-Demethoxyafromosin

Mycotech

Myconate HB

Neochanin